VANCOUVER, British Columbia — A portable device may eliminate the need for sedated electroretinograms in screening for retinal disease in children with nystagmus, according to a scientific poster presented here.At the American Association for Pediatric Ophthalmology and Strabismus meeting, Sara F. Grace, MD, and colleagues presented results of a study using the RETeval (LKC Technologies), which allows electroretinogram screening without general anesthesia.
LOS ANGELES–(BUSINESS WIRE)–Researchers at The Saban Research Institute of Children’s Hospital Los Angeles (CHLA) have demonstrated that targeting survivin – a protein that inhibits apoptosis or cell death – enhances the effectiveness of chemotherapy in cells and mouse models of retinoblastoma (Rb), the most common malignant tumor of the eye in children. The study – led by Charles Gomer, PhD, of the Children’s Center for Cancer and Blood Diseases at CHLA and Jonathan Kim, MD, director of the
A small, single-center study has suggested untreated sleep apnea reduces treatment response to bevacizumab in patients with exudative age-related macular degeneration. Medscape Medical News
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that Olav B. Bergheim, 65, will retire from the company’s board of directors. Mr. Bergheim, who has been a member of the board since he co-founded Glaukos in 1998, will continue to serve as a director until his current term expires
Trachomatous trichiasis (TT, inturning of the eyelashes to touch the eye following longterm infection with Chlamydia trachomatis) affects over seven million people world-wide.
Is this combined procedure a safe and effective alternative treatment option for refractory glaucoma? Journal of Glaucoma